Abstract
Hans Schmoll speaks to Rachel Jenkins, Managing Commissioning Editor.
Over four decades of professional activity, Hans has become one of the most highly esteemed and influential medical oncologists in Germany. As Editor of the German standard reference book for medical and multidisciplinary oncology (6000 pages) [1], he has defined treatment standards and education in medical oncology in the German speaking countries. His work as a research scientist has covered numerous fields in medical oncology, in particular, genitourinary and gastrointestinal cancers, where he has defined worldwide standards for the management of germ-cell cancer and early and late stages of colon cancer. Within the European Society of Medical Oncology, he served on the Executive Board as founding chair of the Multidisciplinary Oncology Committee and as scientific chair of the Istanbul European Society of Medical Oncology Congress 2006.
References
- 1. . Possinger K. In: [Compendium of Internal Oncology] (4th Edition). Springer, Heidelberg, Germany (2006).
- 2. . FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer? Lancet Gastroenterol. Hepatol. 3(3), 143–145 (2018).
- 3. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: results of the DATECAN initiative. Eur. J. Cancer 130, 63–71 (2020).
- 4. MODUL-a Multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J. Cancer Res. Clin. Oncol. 144(6), 1197–1204 (2018).
- 5. Personalizing survival predictions in advanced colorectal cancer: The ARCAD nomogram project. J. Natl Cancer Inst. 110(6), 638–648 (2018).
- 6. . Understanding patient-reported outcome measures in colorectal cancer. Future Oncol. 15(10), 1135–1146 (2019).
